Open report — full analysis, no account required.
Sign up to generate reports and read filings that aren't on the open list.
Get notified when PROK files again. Create a free account and we'll email you the moment its next filing is analyzed.
Get filing alertsProKidney confirms mid-2026 Phase 3 enrollment completion, Q2 2027 pivotal results expected
Filed May 15, 2026 · Period ending May 15, 2026 · ~1 min read
Key Changes
-
high
Phase 3 PROACT 1 trial enrollment on track to complete mid-2026, with pivotal topline results expected Q2 2027. This timeline determines when ProKidney could seek FDA approval for rilparencel in chronic kidney disease.
Item 7.01 verify on EDGAR → -
high
FDA agreed 1.5 mL/min/1.73m² improvement in kidney function decline would support approval under RMAT designation. Trial powered at 80% to detect this threshold, reducing regulatory uncertainty about what constitutes success.
Item 7.01 verify on EDGAR → -
medium
Phase 2 data showed 4.6 mL/min/1.73m² improvement, exceeding the 1.5 FDA threshold by 3x. While promising context, Phase 2 results don't guarantee Phase 3 outcomes.
Item 7.01 verify on EDGAR → -
medium
Statistical powering for surrogate endpoint analysis updated to 80%, matching confirmatory endpoint. This technical adjustment affects trial design for detecting treatment effects on kidney function.
Item 7.01 verify on EDGAR → -
medium
Q1 2026 financial results announced via press release. Detailed financials contained in attached exhibit not summarized in this filing.
Item 2.02 verify on EDGAR →
Summary
ProKidney provided a critical update on its Phase 3 PROACT 1 trial timeline, confirming enrollment will complete mid-2026 with pivotal results expected in Q2 2027. This sets the clock for when the company could potentially seek FDA approval for rilparencel, its cell therapy for chronic kidney disease.
The company emphasized that the FDA has agreed a 1.5 mL/min/1.73m² improvement in kidney function decline would support approval under the RMAT pathway, and the trial is powered at 80% to detect this effect. Retail investors should note the regulatory clarity reduces uncertainty about trial success criteria.
Phase 2 data showed a 4.6 mL/min/1.73m² improvement, well above the FDA threshold, though larger Phase 3 trials often show smaller effects. The company also disclosed a technical adjustment to statistical powering assumptions for the surrogate endpoint analysis. Watch for enrollment completion announcements in mid-2026 and any interim safety updates. The Q2 2027 topline results will be the make-or-break moment determining whether rilparencel advances toward commercialization.
Section-by-Section Diff
Event · Item 2.02 — Results of Operations and Financial Condition
Item 2.02 — Results of Operations and Financial Condition filed; see Key Changes for terms.
Added in current filing · verify on EDGAR →
On May 15, 2026, ProKidney Corp. (the "Company") issued a press release to announce its financial results for the quarter ended March 31, 2026.
The company disclosed its financial results for the first quarter of 2026 ending March 31. The actual financial details are contained in the press release attached as Exhibit 99.1, which is not included in this 8-K body text.
Event · Item 7.01 — Regulation FD Disclosure
Item 7.01 — Regulation FD Disclosure filed; see Key Changes for terms.
Added in current filing · verify on EDGAR →
The PROACT 1 study is expected to have 90% power to detect an effect size in annualized eGFR slope of 1.75 mL/min/1.73m2, and 80% power to detect an effect size in annualized eGFR slope of 1.5 mL/min/1.73m2.
The trial is designed to detect kidney function improvements of 1.5 to 1.75 mL/min/1.73m2 in eGFR slope with high statistical confidence. These thresholds define the minimum efficacy needed to demonstrate the drug works, with the FDA having agreed that 1.5 mL/min/1.73m2 would be acceptable for approval.
Show 1 minor / wording change
Added in current filing · verify on EDGAR →
The Company has updated its investor presentation (the “Presentation”), which its senior management intends to use from time to time when interacting with investors and analysts, among others.
ProKidney has refreshed its investor presentation materials, which management will use in ongoing discussions with investors and analysts. The presentation is available on the company's investor relations website.
Event · Item 8.01 — Other Events
Item 8.01 — Other Events filed; see Key Changes for terms.
Added in current filing · verify on EDGAR →
The statistical powering assumption for the surrogate endpoint (eGFR slope) analysis in the PROACT 1 study has been updated to 80%, while the statistical powering assumption for the confirmatory endpoint analysis remains at 80%.
ProKidney disclosed that the statistical powering assumption for the surrogate endpoint (eGFR slope) analysis in its PROACT 1 clinical trial has been updated to 80%. The confirmatory endpoint analysis remains powered at 80%. This change affects how the trial is designed to detect treatment effects on kidney function decline.
Event · Item 9.01 — Financial Statements and Exhibits
PROKIDNEY CORP. filed an 8-K attaching a press release and investor presentation dated May 15, 2026.
Added in current filing · verify on EDGAR →
99.1 | Press Release dated May 15, 2026 | 99.2 | Investor Presentation
The company filed an 8-K to announce the attachment of a press release and investor presentation both dated May 15, 2026. Without access to the actual exhibits, the materiality and content of these documents cannot be determined from this filing alone.
Thanks — your feedback helps us improve report quality.
Figures/quotes linked to EDGAR · Narrative written by AI · Jun 1, 2026 · How we verify